- Vedam-Mai, Vinata;
- Deisseroth, Karl;
- Giordano, James;
- Lazaro-Munoz, Gabriel;
- Chiong, Winston;
- Suthana, Nanthia;
- Langevin, Jean-Philippe;
- Gill, Jay;
- Goodman, Wayne;
- Provenza, Nicole R;
- Halpern, Casey H;
- Shivacharan, Rajat S;
- Cunningham, Tricia N;
- Sheth, Sameer A;
- Pouratian, Nader;
- Scangos, Katherine W;
- Mayberg, Helen S;
- Horn, Andreas;
- Johnson, Kara A;
- Butson, Christopher R;
- Gilron, Ro'ee;
- de Hemptinne, Coralie;
- Wilt, Robert;
- Yaroshinsky, Maria;
- Little, Simon;
- Starr, Philip;
- Worrell, Greg;
- Shirvalkar, Prasad;
- Chang, Edward;
- Volkmann, Jens;
- Muthuraman, Muthuraman;
- Groppa, Sergiu;
- Kühn, Andrea A;
- Li, Luming;
- Johnson, Matthew;
- Otto, Kevin J;
- Raike, Robert;
- Goetz, Steve;
- Wu, Chengyuan;
- Silburn, Peter;
- Cheeran, Binith;
- Pathak, Yagna J;
- Malekmohammadi, Mahsa;
- Gunduz, Aysegul;
- Wong, Joshua K;
- Cernera, Stephanie;
- Hu, Wei;
- Wagle Shukla, Aparna;
- Ramirez-Zamora, Adolfo;
- Deeb, Wissam;
- Patterson, Addie;
- Foote, Kelly D;
- Okun, Michael S
We estimate that 208,000 deep brain stimulation (DBS) devices have been implanted to address neurological and neuropsychiatric disorders worldwide. DBS Think Tank presenters pooled data and determined that DBS expanded in its scope and has been applied to multiple brain disorders in an effort to modulate neural circuitry. The DBS Think Tank was founded in 2012 providing a space where clinicians, engineers, researchers from industry and academia discuss current and emerging DBS technologies and logistical and ethical issues facing the field. The emphasis is on cutting edge research and collaboration aimed to advance the DBS field. The Eighth Annual DBS Think Tank was held virtually on September 1 and 2, 2020 (Zoom Video Communications) due to restrictions related to the COVID-19 pandemic. The meeting focused on advances in: (1) optogenetics as a tool for comprehending neurobiology of diseases and on optogenetically-inspired DBS, (2) cutting edge of emerging DBS technologies, (3) ethical issues affecting DBS research and access to care, (4) neuromodulatory approaches for depression, (5) advancing novel hardware, software and imaging methodologies, (6) use of neurophysiological signals in adaptive neurostimulation, and (7) use of more advanced technologies to improve DBS clinical outcomes. There were 178 attendees who participated in a DBS Think Tank survey, which revealed the expansion of DBS into several indications such as obesity, post-traumatic stress disorder, addiction and Alzheimer's disease. This proceedings summarizes the advances discussed at the Eighth Annual DBS Think Tank.